A 46-year-old woman was diagnosed in 2013 with a choroid melanoma treated with plaque brachytherapy. A year later, metastatic disease in the liver was confirmed with biopsy and chemotherapy with Dacarbazine was administered. After three cycles, a computerized tomography (CT) evidence disease progression in the liver and therapy with the anti-CTLA4 antibody, Ipilimumab, was started (Dose: 3 mg/Kg. Total dose per cycle: 180 mg). One week after the fourth administration, the patient was remitted to our department because of generalized pruritus and cutaneous lesions on the lower limbs. Clinical examination revealed bilateral and symmetrical erythematous pretibial plaques and nodules (FIG. 1). Both lesions were biopsied, and pathology showed noncaseating granulomas in the dermis consistent with sarcoidosis (FIG. 2). Blood tests revealed an increased angiotensin-converting enzyme (107 U/L. Normal range, 8-52 U/L). The pretibial plaques were treated with topical clobetasol with a significant improvement. During radiological follow-up progression of the liver metastatic disease was detected and administration of Ipilimumab was stopped following the induction therapy, replacing the treatment.The patient is now participating in a new clinical trial. One month after discontinued Ipilimumab she reported progressive dyspnea. CT showed a new nodule on the right lower lobe and fibrous tracts and functional lung tests revealed severe decrease in carbon monoxide diffusing capacity (20% of predicted value). A bronchoscopy was normal and the broncho-alveolar lavage showed lymphocytosis with an inverted CD4:CD8 ratio (0.36). Although the CD4/CD8 ratio is usually high in pulmonary sarcoidosis, it was decided to initiate treatment with oral corticosteroids. After a few days the patient showed clinical improvement without relapse of dyspnea until now. DiscussionIpilimumab is a humanized monoclonal antibody against cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) which has proved to increase survival in patients with metastatic melanoma (1). CTLA-4 is a negative regulator of T-cell activation so its blockade is thought to enhance an antitumor immune response. Its mechanism of action may be responsible for autoimmune adverse events like enterocolitis, hypophysitis, dermatitis, uveitis, vitiligo, arthritis, or hepatitis. A recent systematic review and meta-analysis tried to assess the incidence and nature of immune related adverse events associated with anti-CTLA-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.